1-Methyl-4-cyclopentyl-3-piperidin | 57070-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methyl-4-cyclopentyl-3-piperidin
• 英文别名: 4-Cyclopentyl-1-methylpiperidin；4-cyclopentyl-1-methyl-piperidine；4-Cyclopentyl-1-methylpiperidine
• CAS: 57070-56-1
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: VIXYKKXMRMDYHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] COMPOUNDS, DEVICES, AND USES THEREOF<br/>[FR] COMPOSÉS, DISPOSITIFS ET UTILISATIONS ASSOCIÉES
  申请人：SIGILON THERAPEUTICS INC

  公开号：WO2018067615A1

  公开（公告）日：2018-04-12

  The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.

  本发明提供化合物，例如，具有式（I）的化合物和药用可接受的盐、溶剂化合物、水合物、互变异构体、立体异构体、同位素标记衍生物及其组合物。还提供包括相同化合物的可植入元件（例如，设备和材料），以及使用方法，例如，用于治疗或预防疾病、紊乱或状况。
• ARYLPHOSPHINE OXIDES FOR INHIBITING KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：EP3715350A1

  公开（公告）日：2020-09-30

  The present invention relates to an arylphosphine oxide having inhibitory effect on protein tyrosine kinases, a pharmaceutical composition containing the same, a preparation and a use thereof. Specifically, the present invention discloses a compound represented by formula (I), a pharmaceutically acceptable salt, crystal form, prodrug, metabolite, hydrate, solvate, stereoisomer or isotope derivative thereof, wherein X, Y, R1, RP1, RP2, R2, W and m are as defined in the description. The compound of the invention can be used in the treatment of ALK-mediated cancer-associated disorders, such as non-small cell lung cancer, breast cancer, neurological tumors, esophageal cancer, soft tissue cancer, lymphoma or leukemia.

  本发明涉及一种对蛋白酪氨酸激酶具有抑制作用的芳基氧化膦、含有该物质的药物组合物、制剂及其用途。具体地说，本发明公开了一种由式（I）代表的化合物、其药学上可接受的盐、晶型、原药、代谢物、水合物、溶解物、立体异构体或同位素衍生物，其中 X、Y、R1、RP1、RP2、R2、W 和 m 如描述中所定义。本发明化合物可用于治疗 ALK 介导的癌症相关疾病，如非小细胞肺癌、乳腺癌、神经系统肿瘤、食管癌、软组织癌、淋巴瘤或白血病。
• TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS
  申请人：Kezar Life Sciences

  公开号：US20220402891A1

  公开（公告）日：2022-12-22

  Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.